Joint Task Force to Counter Illicit Synthetic Narcotics Act of 2025
- Bill Number
- H.R. 2024
- Origin Chamber
- House
- Congress
- 119th Congress, Session 1
- Policy Area
- Crime and Law Enforcement
- Status
- Introduced
- Latest Action
- 2025-03-11: Referred to the Committee on the Judiciary, and in addition to the Committees on Financial Services, Foreign Affairs, and Intelligence (Permanent Select), for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
- Last Updated
- 2025-12-05T22:52:02Z
AI-Generated Summary
Purpose of the Legislation
This bill aims to create a centralized federal task force to coordinate efforts across government agencies to combat the trafficking of illicit synthetic narcotics, particularly opioids, which contribute to widespread substance abuse and deaths in the United States. It addresses the lack of a unified entity for information sharing and joint operations against this crisis.
Key Provisions
- Establishment and Leadership: Creates the Joint Task Force to Counter Illicit Synthetic Narcotics (JTF-ISN), led by a Director appointed by the President with Senate confirmation. The Director reports to the Attorney General and is compensated at a high executive pay level (Executive Schedule Level II).
- Membership: Includes representatives from key federal entities, such as the Department of Justice (e.g., Drug Enforcement Administration, FBI), Department of the Treasury (e.g., Financial Crimes Enforcement Network, Office of Foreign Assets Control), Department of Homeland Security (e.g., Customs and Border Protection, Coast Guard), Department of State, Department of Commerce, Department of Defense, Office of the Director of National Intelligence, and any other agencies deemed necessary by the Director.
- Definitions: Defines "illicit synthetic narcotic" as controlled substances (excluding natural-origin substances or legally imported medications), listed chemicals, and ingredients used in their production. Other terms include standard references to controlled substances under federal drug laws.
- Primary Missions: Focuses on directing investigations, disruptions, prosecutions, and strategic coordination against opioid and synthetic narcotic trafficking. Emphasizes joint operations, raids, sanctions enforcement, and legal actions against traffickers, with a particular focus on the role of the People's Republic of China in the crisis.
- Authorities and Limitations: Grants powers to investigate and prosecute federal crimes like trafficking, money laundering, smuggling, and false statements; facilitate information sharing; develop strategies targeting China; and conduct operational activities like raids. Prosecutions involving non-U.S. persons abroad can occur in specific federal districts. Limits activities to counter-opioid efforts tied to synthetic narcotics networks, prohibiting pursuits unrelated to these missions.
- Internal Structure:
- Intelligence coordination element for analyzing trafficking from all intelligence sources.
- Strategic operational planning element for creating and monitoring counter-opioid plans, including interagency roles.
- Office of General Counsel for legal advice.
- Office of Congressional Coordination for managing communications and compliance with reporting.
- Reporting Requirements: Biannual reports and briefings to congressional committees (e.g., Judiciary, Homeland Security) on a 2-year comprehensive plan (goals, improvements, funding needs), budget priorities, enforcement efforts (raids, seizures, indictments, convictions), and actions addressing China's involvement.
- Other Rules: Member agencies retain their existing investigative and prosecutorial powers. The task force cannot target personal drug use or low-level dealing without ties to larger networks.
Significant Changes to Existing Law
- Introduces a new interagency task force as a central hub for coordination, filling a gap noted in congressional findings where no such entity existed for sharing information and aligning efforts across federal, state, territorial, Tribal, and local levels.
- Expands prosecutorial flexibility for international cases by specifying venue options (e.g., district of the crime or DEA headquarters location), which builds on but clarifies existing federal jurisdiction under 18 U.S.C. § 3238.
- Mandates focused strategies and reporting on foreign actors like China, integrating sanctions and international cooperation more explicitly into domestic drug enforcement frameworks.
Potential Impacts
- Government Agencies: Enhances interagency collaboration, potentially streamlining investigations and operations to disrupt trafficking networks more efficiently, though it may require additional funding and staff as outlined in reports.
- Citizens: Could reduce opioid-related deaths (hundreds of thousands annually) by improving enforcement against suppliers and traffickers, indirectly supporting public health and safety in affected communities.
- International Relations: May increase tensions with countries like China through targeted investigations, sanctions, and prosecutions of foreign entities, but could also foster cooperative law enforcement via joint operations and information sharing.
Main Stakeholders Affected
- Federal Agencies: Departments of Justice, Treasury, Homeland Security, State, Commerce, Defense, and intelligence community—required to participate, share resources, and align operations.
- Law Enforcement: State, territorial, Tribal, and local agencies, which gain opportunities for coordinated actions like joint raids and prosecutions.
- Congress: Receives mandatory reports and briefings, influencing oversight and funding decisions.
- Communities and Individuals: Those impacted by the opioid crisis (e.g., victims' families, addicts) may benefit from reduced trafficking; traffickers and networks face heightened scrutiny.
- Foreign Entities: Particularly suppliers in China, subject to U.S. legal actions, sanctions, and diplomatic pressure.
Notable Legal, Constitutional, or Political Implications
- Legal: Strengthens enforcement against synthetic narcotics by centralizing authority without overriding existing agency powers, but includes safeguards (e.g., no low-level targeting) to avoid overreach. Relies on definitions from the Controlled Substances Act (21 U.S.C. § 802), ensuring consistency with current drug laws.
- Constitutional: Upholds separation of powers through Senate confirmation for the Director and congressional reporting/briefing requirements, providing oversight and checks on executive actions.
- Political: Bipartisan sponsorship highlights consensus on the opioid crisis as a national priority; the emphasis on China introduces a geopolitical dimension, potentially influencing U.S. foreign policy and trade relations without direct bias in the bill's text.
This summary was generated by AI and may contain inaccuracies. Refer to the official source document for the authoritative text.
Sponsor
Cosponsors (9)
Rep. Moolenaar, John R. [R-MI-2], Rep. Krishnamoorthi, Raja [D-IL-8], Rep. Auchincloss, Jake [D-MA-4], Rep. Dunn, Neal P. [R-FL-2], Rep. Khanna, Ro [D-CA-17], Rep. Johnson, Dusty [R-SD-At Large], Rep. Torres, Ritchie [D-NY-15], Rep. Gillen, Laura [D-NY-4], Rep. Vindman, Eugene Simon [D-VA-7]
Recent Actions
- 2025-03-11: Referred to the Committee on the Judiciary, and in addition to the Committees on Financial Services, Foreign Affairs, and Intelligence (Permanent Select), for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
- 2025-03-11: Referred to the Committee on the Judiciary, and in addition to the Committees on Financial Services, Foreign Affairs, and Intelligence (Permanent Select), for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
- 2025-03-11: Referred to the Committee on the Judiciary, and in addition to the Committees on Financial Services, Foreign Affairs, and Intelligence (Permanent Select), for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
- 2025-03-11: Referred to the Committee on the Judiciary, and in addition to the Committees on Financial Services, Foreign Affairs, and Intelligence (Permanent Select), for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
- 2025-03-11: Introduced in House
- 2025-03-11: Introduced in House
Bill Versions
- Joint Task Force to Counter Illicit Synthetic Narcotics Act of 2025 — issued 2025-03-11 — PDF (11 pages)